AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02166723 — intervention group
Intervention type: DEVICE
Intervention: cryoballoon ablation
Description: A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. In each patient the left atrium was debulked by applying cryoballoon to the left and right sides of the left atrial roof and cryoablation of the left lateral ridge from within the left atrial appendage.
Study NCT03596775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Children in Dexmedetomidine group receive intravenous dexmedetomidine 0.5 ug/kg over 10 minutes after induction of anesthesia.
Study NCT03596775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Children in Control Comparator group receive intravenous saline 10ml over 10 minutes after induction of anesthesia.
Study NCT03991052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EV1000 and closed-loop system
Description: This system will recommend when patients need fluid or not and adjust vasopressor administration automatically by the closed-loop system
Study NCT03842449 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological samples
Description: The nature of the samples taken during the delivery are:~* maternal blood,~* cord blood~* placenta fragment
Study NCT03842449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples
Description: The nature of the samples taken during the delivery are:~* maternal blood,~* cord blood~* placenta fragment
Study NCT01408953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab will be diluted with 0.9% Sodium Chloride to achieve a concentration of 1 mg/0.3 ml. Bevacizumab will be injected inside ONE keloid tissue to result in a visual expansion of the keloid. Only 1 mg of bevacizumab is injected inside ONE keloid. The injections will be repeated every 14 days. Patients will receive maximum of 12 injections only.~A log will be kept for each patient indicating the date and the dose of bevacizumab that was delivered to each patient.
Study NCT02484352 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: saline
Description: different dosage of IV oxycodone was given before intubation
Study NCT02484352 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.05 mg/kg of oxycodone
Description: different dosage of IV oxycodone was given before intubation
Study NCT02484352 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.1 mg/kg of oxycodone
Description: different dosage of IV oxycodone was given before intubation
Study NCT02484352 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.15 mg/kg of oxycodone
Description: different dosage of IV oxycodone was given before intubation
Study NCT02484352 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.2 mg/kg of oxycodone
Description: different dosage of IV oxycodone was given before intubation
Study NCT00306527 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cell culture derived influenza vaccine
Description: as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
Study NCT00306527 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: egg-derived influenza subunit vaccine
Description: as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
Study NCT02930304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: first physiotherapy
Description: physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions
Study NCT02930304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: second physiotherapy
Description: physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Kinesio taping will be applied two times per week total six times in addition to conventional physiotherapy
Study NCT02930304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: third physiotherapy
Description: physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Extracorporeal shockwave therapy (ESWT) will be applied one times per week total three session.
Study NCT03437577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: immediate-release tacrolimus
Description: Standard of care for transplant patients
Study NCT03437577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release tacrolimus
Description: Experimental care
Study NCT04348981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable fitness tracking device
Description: Patients having a wearable fitness tracking device will be monitored for their level of activity after surgery. Declines in activity level will prompt a phone call from the surgical provider.
Study NCT04369976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTIFICIAL GRAVITY COMBINED WITH EXERCISE
Description: The passive control group will abstain from any exercise. Recordings of the participant's will include cardiovascular functioning cardiac output (CO), stroke volume (SV) mean arterial pressure (MAP) diastolic blood pressure (DBP), systolic blood pressure (SBP), and heart rate (HR), Electroencephalography ( EEG) as well as dynamic force and stance and muscle oxygenation. More specifically, after 6 training sessions (2 weeks), the centrifugation load will be increased and will be combined with either aerobic exercise (through an ergometer) or resistance training through elastic training bands. Functional connectivity and cortical-network features will be used by deep learning algorithms in order to define the optimal centrifuge training .
Study NCT02767661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine, 500mg, orally three times daily (continuously)
Study NCT02767661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitor
Description: Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)
Study NCT02767661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)
Study NCT02144025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Use of topical cyclosporine (one drop of cyclosporine in each eye, twice a day for 12 months)
Study NCT00777361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: Iv single dose, 4-hour infusion of 25 mg
Study NCT00777361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: Oral solution single dose of 50 mg
Study NCT02870634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu(II)ATSM
Description: copper-containing synthetic small molecule
Study NCT03365310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C. longa, curcuminoids , Z. officianale, O. sanctum along with 200 ml of Milk
Description: Polyherbal formulation along with standard of care
Study NCT03365310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Usual standard of care for consist of exercise, caloric and protein support, vitamin D, reduction of polypharmacy along with medical management of health condition, assessment of care needs and provision of care. These will be determined on case by case basis by research clinician.
Study NCT03365310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Usual standard of care for consist of exercise, caloric and protein support, vitamin D, reduction of polypharmacy along with medical management of health condition, assessment of care needs and provision of care. These will be determined on case by case basis by research clinician.
Study NCT04171037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen Therapy
Description: Receive oxygen via Optiflow THRIVE
Study NCT04171037 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Therapy
Description: Receive oxygen via non-rebreather
Study NCT04171037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04171037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04171037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow THRIVE
Description: Oxygen Administration
Study NCT02669368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
Study NCT02669368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
Study NCT02669368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose Rocuronium
Description: 0.6 mg/kg of Rocuronium given with induction of anesthesia
Study NCT02669368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose Rocuronium
Description: 0.45 mg/kg of Rocuronium given with induction of anesthesia
Study NCT03637465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hydrate Philly
Description: Hydrate Philly is a multi-component intervention that includes water safety testing, provision of 1-2 hydration stations per recreation center, distribution of reusable water bottles for youth, a campaign to promote the acceptability of tap water, and the reduction of access to competing unhealthy beverages through vending machine standards and discouraging black bags (characteristic small, black, plastic bags provided to customers with their corner store purchases, typically including a sugar sweetened beverage and/or unhealthy snack foods).
Study NCT03615807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical debridement (if needed)
Description: Surgical debridement
Study NCT03615807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical debridement (if needed)
Description: Surgical debridement
Study NCT03615807 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microbiological sampling
Description: Microbiological sampling
Study NCT03615807 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Microbiological sampling
Description: Microbiological sampling
Study NCT03615807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revascularisation (if needed).
Description: Revascularisation (if needed).
Study NCT03615807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Revascularisation (if needed).
Description: Revascularisation (if needed).
Study NCT03615807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Off-loading
Description: Off-loading by Special shoes
Study NCT03306511 — intervention group
Intervention type: OTHER
Intervention: Repeated-sprint test
Description: 6x30-meter sprint interspersed with 90-s rest
Study NCT03155438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oxidative stress-related gene expression (RNA expression)
Description: Oxidative stress-related gene expression (RNA expression),Superoxide dismutase 1 (SOD1) , SOD2 , Glutathione peroxidase (GPX) and Inducible nitric oxide synthase (iNOS) , measured by Real time PCR technique.
Study NCT03155438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: oocyte competence biomarkers
Description: Oocyte competence biomarkers ,GDF9, BMP15, Amphiregulin and CoQ10 measured by ELISA
Study NCT00067379 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interceptive orthodontic treatments
Description: orthodontic procedures
Study NCT00321815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676 + Erlotinib
Description: PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity.~Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
Study NCT03615807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Off-loading
Description: Off-loading by Special shoes
Study NCT03615807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient's education and instructions
Description: Patient's education and instructions by specialized nurses
Study NCT00321815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
Study NCT04050813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercises program for hamstring architecture and function
Description: To assess the effectiveness of the inertial flywheel resistance program in the architecture and function of the hamstrings post structural hamstring injury
Study NCT03615807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient's education and instructions
Description: Patient's education and instructions by specialized nurses
Study NCT03615807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound debridement
Description: Regular wound debridement by specialized nurses
Study NCT03615807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound debridement
Description: Regular wound debridement by specialized nurses
Study NCT03615807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic duration
Description: Systemic antibiotic duration according to the study arms
Study NCT03615807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic duration
Description: Systemic antibiotic duration according to the study arms
Study NCT01262482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2, IV during 2 hours on day 1 of each 21 day cycle. Number of cycles: until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
Study NCT01262482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400mg, orally, 2 times per day. Until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
Study NCT03606954 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination topical corticosteroid
Description: Comparison of a vasoconstriction index between the 2 study arms
Study NCT03561415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Universal Posaconazole Prophylaxis
Description: All patients assigned to this arm will start posaconazole between Day 4 and Day 14 post lung or heart-lung transplant for a minimum of 3 months.
Study NCT03561415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-emptive Posaconazole Therapy
Description: Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease for 3 months.
Study NCT00176592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betaseron
Description: Betaseron 250 micrograms injected SQ every other day
Study NCT00176592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone
Description: Copaxone 20 mg injected SQ every day (glatiramer acetate)
Study NCT00884299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet rich in antioxidants
Description: Dietary intervention based on diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients are advised by a physician and a specialist nurse during regular scheduled outpatient clinic visits to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the study period.
Study NCT00973479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
Study NCT00973479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab
Description: Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
Study NCT00973479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
Study NCT00973479 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
Study NCT00973479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate (MTX)
Description: Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
Study NCT00973479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate (MTX)
Description: Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
Study NCT04332289 — intervention group
Intervention type: OTHER
Intervention: Heavy water experiment
Description: 3 times daily heavy water (deuterated-water) and mixed meal administration for one week
Study NCT00771524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Description: Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
Study NCT03991052 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: This system will recommend when patients need fluid or not and nurses will adjust vasopressor administration as usual (standard of care)
Study NCT02578056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Midurethral sling
Description: Anti-urinary incontinence procedure, in a prophylactic way.
Study NCT02578056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genital prolapse surgery
Description: Surgical correction of genital prolapse
Study NCT02578056 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Genital prolapse surgery
Description: Surgical correction of genital prolapse
Study NCT03392649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym
Description: Tragus stimulation was done using the Parasym device.
Study NCT02106494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APF530
Study NCT02106494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Study NCT02106494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron placebo
Study NCT02106494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APF530 placebo
Study NCT02106494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Study NCT02106494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosaprepitant
Study NCT02106494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02106494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT03963115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine or normal saline
Description: epinephreine or normal saline coated syringe before drawing allergen for injection.
Study NCT03963115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epinephrine or normal saline
Description: epinephreine or normal saline coated syringe before drawing allergen for injection.
Study NCT01425879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT01425879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01425879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies